Journal of Neoplasm

Sunitinib as Neoadjuvant Treatment of Neuroendocrine Pancreatic Tumors: Case Report

Pancreatic Neuroendocrine Tumors (PNETs) are rare tumors. Surgery is the only potential treatment for cure. There is a paucity of data to support an optimal neoadjuvant approach for inoperable tumors. We present a case of 39-year-old women admitted for management of nonfunctioning locally advanced PNET with the invasion of the Superior Mesenteric Vein (SMV) and duodenum. The patient received neoadjuvant treatment by sunitinib (37.5 mg/day). After 8 weeks of treatment, the tumor was successfully resected and the patient has remained recurrent free for 18 months. Sunitinib seems to be a valuable option in the neoadjuvant setting for nonfunctioning locally advanced PNET.

Author(s):

O Al Jarroudi, T El harroudi, B Serji, T Bouhout, E Eggyr, A Zaimi, L Jaouani, SA Brahmi, S Afqir

Abstract | Full-Text | PDF

Share this